Novo Nordisk has announced that the company filed a lawsuit against Pfizer claiming that Pfizer's product Exubera infringes patents owned by Novo Nordisk. The patents cover inhaled insulin treatme
Ranbaxy announced today that the U.S. Court of Appeals for the Federal Circuit (CAFC) handed down a judgment in its case challenging two key atorvastatin patents held by Pfizer. Atorvastatin is
Oragenics has announced that the US Patent office has issued a fourth patent (No. 7,067,125), that further describes the composition and uses of the company's exclusively licensed novel antibiotic p
Rapid analysis and response in the very early stages of a pandemic or bioterrorism event can sharply limit its deadly impact. Surprisingly, a key early warning sensor for biologically- related illnesses may be the human body itself and American
Archus Orthopedics has announced that it has been awarded its seventh United States Patent. Arising from a 1999 patent application filed by the company's founder, Mark Reiley, M.D., U.S. Pat
Palomar Medical Technologies has announced that it filed a lawsuit in the U.S. District Court for the District of Massachusetts against Candela Corporation for patent infringement. In th
Boston Life Sciences has announced that the U.S. Patent and Trademark Office has issued a patent to the President and Fellows of Harvard College, the General Hospital Corporation and Organix
ZymoGenetic has announced that it has filed a lawsuit against Bristol-Myers Squibb for infringement of its patents related to fusion protein technology. In the lawsuit filed with the United State
Ryogen and OriGene Technologies have announced today that they have entered into a nonexclusive license agreement whereby OriGene has licensed from R
Morphotek has announced that the European Patent Office has given a "Decision of Grant" regarding the Company's US Patent 6,921,666 entitled "Methods for Generating Hypermutable Yeast" and US Patent 6,737,268 entitled "A Method for Generating Genetical
Date: Monday, 11-Sep-2006
Mylan Laboratories Inc. has announced that the U.S. Court of Appeals for the Federal Circuit upheld a district court decision that Mylan's Oxybutynin products do not infringe a patent for DITROPAN XL and that the patent was invalid.Mylan has received tentative approval and is currently awaiting final approval from the United States Food and Drug Administration (FDA) for its 5 and 10 mg strengths of Oxybutynin. Mylan is the first generic company to file Abbreviated New Drug Applications (ANDAs) for these two strengths, and will therefore be eligible for 180-days of market exclusivity upon commercial launch. The 5 and 10 mg strengths represent more than 80% of the approximately $380 million in U.S. sales during the 12-month period ended June 30, 2006, according to IMS. The Company also entered into exclusive supply agreements with Ortho-McNeil Pharmaceuticals, Inc. and Alza Corporation which would allow for Mylan to launch all three strengths of DITROPAN XL.
Robert J. Coury, Mylan's Vice Chairman and Chief Executive Officer commented: "We are pleased with the appellate court's decision and expect to launch all three strengths of this product. Oxybutynin is the latest in a series of difficult to formulate products that Mylan over the many years has been able to successfully develop."
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries: Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.
http://www.mylan.com/